Table 2. Characteristics and risk factors for case-patients with mpox confirmed or highly probable according to specimens collected in 2023, England*.

Variable	No. (%), n = 128†
HIV status
Living with HIV	13 (10)
HIV negative	69 (54)
Taking HIV PrEP‡	51 (74)
Not taking PrEP‡	18 (26)
Unknown	46 (36)
Modified Vaccinia Ankara–Bavarian Nordic vaccination status§
Vaccinated: >2 doses¶	30 (23)
Vaccinated: 1 dose	20 (16)
Vaccinated: no. doses unknown	2 (2)
Unvaccinated	54 (42)
Unknown	22 (17)
Childhood smallpox vaccination status
Vaccinated	4 (3)
Unknown	124 (97)
Hospital admission
Yes	11 (9)
No	117 (91)
Unknown
Reporting attending events involving multiple sex partners
Yes	28 (22)
No	17 (13)
Unknown	83 (65)
Concurrent STI
Yes	24 (19)
No	28 (22)
Unknown	76 (59)

*Patients were median 36 years of age, range 19–70 years, interquartile range 29–24 years. PrEP, preexposure prophylaxis; STI, sexually transmitted infection. †Unless otherwise stated, denominators are 128; denominators for percentage calculations are HIV-negative persons. ‡We do not have information on HIV treatment or outcomes of treatment for these cases. Nevertheless, most people living with HIV in England take antiretroviral therapy and have an undetectable viral load (8). §Estimated date of vaccination was available for 33 out of 52 vaccinated cases, all of whom received the Modified Vaccinia Ankara–Bavarian Nordic vaccine >2 weeks before infection. ¶Includes 1 person who reported receiving 3 doses.